Alpha Tau Medical to Participate in September Investor Conferences

2 years ago

JERUSALEM, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ: DRTS, DRTSW), the…

Recce Pharmaceuticals Doses Patients in Phase I/II Clinical Trial of RECCE® 327 for Diabetic Foot Infections

2 years ago

Patients dosed in Phase I/II trial, evaluating RECCE® 327 (R327) in patients with diabetic foot infections (DFI), currently the largest…

aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

2 years ago

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery…

NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors

2 years ago

SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company…

STRATA Skin Sciences to Host Virtual KOL Event on XTRAC® and TheraClear®X

2 years ago

HORSHAM, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to…

Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome  

2 years ago

Fast Track Designation (FTD) is designed to accelerate the development and expedite the review of therapies with potential to address…

Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer

2 years ago

Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancerSYDNEY, Australia, Aug.…

Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026

2 years ago

STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed…

LumiraDx Reports Second Quarter 2023 Results

2 years ago

LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today…

Societal CDMO Announces Pricing of $8.3 Million Public Offering of Common Stock

2 years ago

SAN DIEGO and GAINESVILLE, Ga., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development…